CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: For instance, quantitative phosphoproteomic analysis of IM-resistant K562 identified Tpl2 (tumor progression locus)-derived phosphopeptide as being highly dysregulated compared to IM-sensitive counterparts, and found a similar scenario in CD34+ CML patient BM cells, identifying MEK-ERK, Src family kinases, and NFκB signaling as potential mediators of IM resistance [198].